Pharmacologic modulation to open the KATP channels with diazoxide is useful in treating hyperinsulinemia. Diazoxide is being used more often in neonates with hyperinsulinemic hypoglycemia. This report highlights a case of severe pulmonary hypertension (PH) with re-opening of ductus arteriosus in an extremely premature infant after the use of diazoxide. The rapid onset of PH with respiratory failure was completely reversible. This case emphasizes the need for extreme caution with use of diazoxide in the premature infant population, especially those with chronic lung disease of prematurity. In addition, the use of diazoxide should be limited to the persistent form of congenital hyperinsulinism, after adequate work up has been completed to eva...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypo...
Persistent pulmonary hypertension of the newborn (PPHN) is a serious and potentially fatal condition...
Ranjit I Kylat Division of Neonatal-Perinatal Medicine and Developmental Biology, Department of Pedi...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
Abstract Introduction: Diazoxide is the first-line treatment used to manage infants and children wit...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
SUMMARY Seven infants with persistent neonatal hyperinsulinism were treated in Dhahran Health Centre...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Background: Premature preterm rupture of membranes (PPROM) is reported to be associ...
Abstract Background Inhaled nitric oxide (iNO) has been approved for the treatment of persistent pul...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypo...
Persistent pulmonary hypertension of the newborn (PPHN) is a serious and potentially fatal condition...
Ranjit I Kylat Division of Neonatal-Perinatal Medicine and Developmental Biology, Department of Pedi...
Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic h...
Background: Diazoxide is the main therapeutic agent for congenital hyperinsulinism. The drug is gene...
Abstract Introduction: Diazoxide is the first-line treatment used to manage infants and children wit...
PubMedID: 18512033Primary persistent hyperinsulinaemic hypoglycaemia is characterised by clinical sy...
SUMMARY Seven infants with persistent neonatal hyperinsulinism were treated in Dhahran Health Centre...
Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, how...
Primary persistent hyperinsulinaemic hypoglycaemia of infancy is rare. Diazoxide treatment remains t...
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI), also known as congenital hyperinsulinism...
WOS: 000418709600016Hyperinsulinemic hypoglycemia (HH) is the most common reason for persistent and ...
Background: Premature preterm rupture of membranes (PPROM) is reported to be associ...
Abstract Background Inhaled nitric oxide (iNO) has been approved for the treatment of persistent pul...
Diazoxide is the first-line treatment for patients with hyperinsulinaemic hypoglycaemia (HH). Approx...
Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypo...
Persistent pulmonary hypertension of the newborn (PPHN) is a serious and potentially fatal condition...